Arya Mariam Roy, MBBS

home / authors / arya-mariam-roy-mbbs

Articles

Arya Mariam Roy, MBBS

Dr Roy on Limitations of the Pathway Trial Evaluating PGS and Survival in Breast Cancer

Arya Mariam Roy, MBBS
July 15th 2024

Arya Mariam Roy, MBBS discusses limitations of the Pathway trial evaluating the association between polygenic scores and survival outcomes in patients with breast cancer.

Read More

Arya Mariam Roy, MBBS

Dr Roy on Polygenic Scores and the Risk of Recurrence in Breast Cancer

Arya Mariam Roy, MBBS
June 14th 2024

Arya Mariam Roy, MBBS, discusses the role of polygenic scores in predicting the risk of recurrence and survival outcomes in breast cancer.

Read More

Neighborhood Plays an Important Role in Clinical Outcomes for Patients With Breast Cancer

Neighborhood Plays an Important Role in Clinical Outcomes for Patients With Breast Cancer

Arya Mariam Roy, MBBS;Shipra Gandhi, MD
July 28th 2023

Addressing socioeconomic health disparities has been a crucial objective of health policy in the United States. The relationship between cancer incidence and mortality and socioeconomic status varies across malignancies.

Read More

Arya Mariam Roy, MBBS

Dr. Roy on the Effect of Neoadjuvant Chemotherapy on OS in Sarcomatoid Bladder Cancer

Arya Mariam Roy, MBBS
February 20th 2023

Arya Mariam Roy, MBBS, discusses the effect of neoadjuvant chemotherapy on overall survival in patients with sarcomatoid muscle-invasive bladder cancer.

Read More

Latest Updated Articles

Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need